A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1590
- Registration Number
- NCT05552222
- Locations
- 🇫🇷
CHU Hopital Saint Antoine, PARIS cedex 12, France
🇫🇷CHU de Bordeaux - Hospital Haut-Leveque, Pessac cedex, France
🇫🇷CHU Lyon Sud, Pierre-Benite, France
A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
- Conditions
- Depressive Disorder, MajorAnhedonia
- Interventions
- Other: Placebo
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 444
- Registration Number
- NCT05550532
- Locations
- 🇦🇷
INSA Instituto de Neurociencias San Agustín, La Plata, Argentina
🇦🇷Clinica Privada de Salud Mental Santa Teresa de Ávila, La Plata, Argentina
🇦🇷C I A P Centro de investigacion y Asistencia en Psiquiatria, Rosario, Argentina
A Single Ascending Dose Study of JNJ-88260237 in Healthy Participants
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT05541315
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Colitis, Ulcerative
- Interventions
- First Posted Date
- 2022-09-06
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 418
- Registration Number
- NCT05528510
- Locations
- 🇦🇷
Hospital Provincial del Centenario, Rosario, Argentina
🇵🇱Centrum Medyczne Promed, Krakow, Poland
🇵🇱Zespol Poradni Specjalistycznych REUMED Filia nr 2, Lublin, Poland
A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 4
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT05522517
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Antwerpen, Belgium
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias
- Conditions
- Acute LeukemiasAcute Leukemia of Ambiguous LineageAcute Myeloid LeukemiaAcute Lymphoblastic Leukemia
- Interventions
- Drug: Intrathecal Chemotherapy
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT05521087
- Locations
- 🇺🇸
Memorial Sloan Kettering, New York, New York, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 840
- Registration Number
- NCT05518149
- Locations
- 🇺🇸
University of Alabama at Birmingham - The Kirklin Clinic, Birmingham, Alabama, United States
🇺🇸SW Biomedical Research LLC, Tucson, Arizona, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma
- Conditions
- Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT05503550
- Locations
- 🇸🇮
DUMMY, Dummy, Slovenia
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-small-Cell Lung
- Interventions
- Drug: Direct Oral Anticoagulant (DOAC)Drug: Low Molecular Weight Heparin (LMWH)
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 390
- Registration Number
- NCT05498428
- Locations
- 🇮🇱
Rambam Medical Center, Haifa, Israel
🇮🇱Shaare Zedek Medical Center, Jerusalem, Israel
🇪🇸General University Hospital of Alicantet, Alacant, Spain
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 57
- Registration Number
- NCT05488314
- Locations
- 🇧🇷
Fundacao Antonio Prudente A C Camargo Cancer Center, Sao Paulo, Brazil
🇨🇳Shengjing Hospital Of China Medical University, Shenyang, China
🇧🇷PERSONAL Oncologia de Precisao e Personalizada, Belo Horizonte, Brazil